DILTIAZEM HYDROCHLORIDE - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for diltiazem hydrochloride and what is the scope of freedom to operate?
Diltiazem hydrochloride
is the generic ingredient in twelve branded drugs marketed by Bausch, Biovail, Actavis Labs Fl Inc, Allergan, Apotex, Accord Hlthcare, Actavis Elizabeth, Amta, Dr Reddys Labs Sa, Endo Operations, Glenmark Pharms Ltd, Mylan, Nesher Pharms, Norvium Bioscience, Novast Labs, Sandoz, Sun Pharm, Teva, Twi Pharms, Valeant Pharms North, Zydus Pharms, Biovail Labs Intl, Dr Reddys, Eugia Pharma, Hikma, Hikma Farmaceutica, Hospira, Intl Medication, Mylan Labs Ltd, Rising, Sagent, Exela Pharma, Sciegen Pharms Inc, Apothecon, Chartwell Molecules, Edenbridge Pharms, Ivax Sub Teva Pharms, and Teva Pharms, and is included in sixty-two NDAs. Additional information is available in the individual branded drug profile pages.There are seventeen drug master file entries for diltiazem hydrochloride. Fifty-two suppliers are listed for this compound.
Summary for DILTIAZEM HYDROCHLORIDE
US Patents: | 0 |
Tradenames: | 12 |
Applicants: | 38 |
NDAs: | 62 |
Drug Master File Entries: | 17 |
Finished Product Suppliers / Packagers: | 52 |
Raw Ingredient (Bulk) Api Vendors: | 131 |
Clinical Trials: | 106 |
Patent Applications: | 4,517 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for DILTIAZEM HYDROCHLORIDE |
What excipients (inactive ingredients) are in DILTIAZEM HYDROCHLORIDE? | DILTIAZEM HYDROCHLORIDE excipients list |
DailyMed Link: | DILTIAZEM HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for DILTIAZEM HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Ascension Genesys Hospital | Phase 2 |
Aurora Health Care | Phase 4 |
Hospices Civils de Lyon | Phase 2 |
Pharmacology for DILTIAZEM HYDROCHLORIDE
Drug Class | Calcium Channel Blocker |
Mechanism of Action | Calcium Channel Antagonists Cytochrome P450 3A4 Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for DILTIAZEM HYDROCHLORIDE
Paragraph IV (Patent) Challenges for DILTIAZEM HYDROCHLORIDE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
CARDIZEM LA | Extended-release Tablets | diltiazem hydrochloride | 120 mg, 180 mg, 240 mg, 300 mg and 360 mg | 021392 | 1 | 2005-08-30 |
CARDIZEM LA | Extended-release Tablets | diltiazem hydrochloride | 420 mg | 021392 | 1 | 2005-04-25 |
US Patents and Regulatory Information for DILTIAZEM HYDROCHLORIDE
Expired US Patents for DILTIAZEM HYDROCHLORIDE
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.